MS News That Caught My Eye Last Week: Orelabrutinib, MS Stress, Selma Blair

MS News That Caught My Eye Last Week: Orelabrutinib, MS Stress, Selma Blair

299890

MS News That Caught My Eye Last Week: Orelabrutinib, MS Stress, Selma Blair

Biogen Strikes Deal for Orelabrutinib, Now in Phase 2 Trial BTK inhibitors, such as orelabrutinib, are designed to selectively block the activity of an enzyme important for the activation of B-cells and microglia. Some of those cells drive the abnormal immune responses that attack the central nervous systems of people with MS. Researchers hope orelabrutinib, which is a capsule, will lower inflammation and slow progression of all MS forms. Biogen thinks the medication has enough…

You must be logged in to read/download the full post.